Omnimmune Competitors
| OMMH Stock | USD 0.0001 0.00 0.00% |
Omnimmune Holdings vs Minerva Surgical Correlation
As of now, Omnimmune Holdings' Return On Capital Employed is increasing as compared to previous years. The Omnimmune Holdings' current Return On Equity is estimated to increase to 0.34, while Return On Tangible Assets are projected to decrease to (67.66). The current Total Assets is estimated to decrease to about 30.1 K. The current Net Tangible Assets is estimated to decrease to about (6.6 M).Omnimmune Holdings Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Omnimmune Holdings and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Omnimmune and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Omnimmune Holdings does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Omnimmune Stock performing well and Omnimmune Holdings Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Omnimmune Holdings' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| EFTR | 6.03 | 0.92 | 0.00 | 1.18 | 0.00 | 0.00 | 266.67 | |||
| CFRXQ | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| ADYX | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| DMKPQ | 26.90 | 11.16 | 0.00 | 1.04 | 0.00 | 0.00 | 990.00 | |||
| LITH | 3.01 | 0.89 | 0.00 | (0.48) | 0.00 | 0.00 | 150.00 | |||
| GRPI | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| ATRX | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| PROT | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| UTRS | 5.34 | (1.37) | 0.00 | (0.80) | 0.00 | 0.00 | 150.00 |
Cross Equities Net Income Analysis
Compare Omnimmune Holdings and related stocks such as Effector Therapeutics, ContraFect, and Adynxx Inc Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EFTR | (29.7 M) | (29.7 M) | (29.7 M) | (29.7 M) | (29.7 M) | (29.7 M) | (29.7 M) | (29.7 M) | (29.7 M) | (29.7 M) | 14.2 M | 15.8 M | (12.9 M) | (35.8 M) | (35.8 M) | (32.2 M) | (30.6 M) |
| LITH | (498.3 K) | (498.3 K) | (498.3 K) | (498.3 K) | (498.3 K) | (82.2 K) | (209.5 K) | (246.9 K) | (337 K) | (337 K) | (337 K) | (337 K) | (337 K) | (337 K) | (337 K) | (387.5 K) | (406.9 K) |
| GRPI | (153.9 K) | (55.6 K) | (55.6 K) | (55.6 K) | (55.6 K) | (55.6 K) | (55.6 K) | (55.6 K) | (55.6 K) | (55.6 K) | (55.6 K) | (55.6 K) | (55.6 K) | (55.6 K) | (55.6 K) | (50 K) | (47.5 K) |
| PROT | (5 M) | (1.4 M) | (1.4 M) | (1.4 M) | (1.4 M) | (1.4 M) | (1.4 M) | (1.4 M) | (1.4 M) | (1.4 M) | (1.4 M) | (1.4 M) | (1.4 M) | (1.4 M) | (1.4 M) | (1.6 M) | (1.7 M) |
Omnimmune Holdings and related stocks such as Effector Therapeutics, ContraFect, and Adynxx Inc Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Omnimmune Holdings financial statement analysis. It represents the amount of money remaining after all of Omnimmune Holdings operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Omnimmune Holdings Competitive Analysis
The better you understand Omnimmune Holdings competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Omnimmune Holdings' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Omnimmune Holdings' competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Omnimmune Holdings Competition Performance Charts
Five steps to successful analysis of Omnimmune Holdings Competition
Omnimmune Holdings' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Omnimmune Holdings in relation to its competition. Omnimmune Holdings' competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Omnimmune Holdings in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Omnimmune Holdings' competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Omnimmune Holdings, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Omnimmune Holdings position
In addition to having Omnimmune Holdings in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Utilities Thematic Idea Now
Utilities
Highly leveraged corporations that deliver utilities such as power, water or gas to public or business. The Utilities theme has 30 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Utilities Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Omnimmune Holdings Correlation with its peers. For more detail on how to invest in Omnimmune Stock please use our How to Invest in Omnimmune Holdings guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is there potential for Biotechnology market expansion? Will Omnimmune introduce new products? Factors like these will boost the valuation of Omnimmune Holdings. Anticipated expansion of Omnimmune directly elevates investor willingness to pay premium valuations. Understanding fair value requires weighing current performance against future potential. All the valuation information about Omnimmune Holdings listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Omnimmune Holdings's market price often diverges from its book value, the accounting figure shown on Omnimmune's balance sheet. Smart investors calculate Omnimmune Holdings' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Since Omnimmune Holdings' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Omnimmune Holdings' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Omnimmune Holdings should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Omnimmune Holdings' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.